Table 3 Adverse events reported by more than one patient in any treatment period (treated set)
Patients, n (%) | ||||
|---|---|---|---|---|
Tiotropium Respimat ® 5 μg | Tiotropium Respimat ® 2.5 μg | Tiotropium Respimat ® 1.25 μg | Placebo Respimat ® | |
(n = 76) | (n = 74) | (n = 75) | (n = 76) | |
Patients with any adverse event | 7 (9.2) | 7 (9.5) | 7 (9.3) | 8 (10.5) |
Asthma | 2 (2.6) | 2 (2.7) | 1 (1.3) | 1 (1.3) |
Bronchitis | 2 (2.6) | 1 (1.4) | 1 (1.3) | 1 (1.3) |
Headache | 1 (1.3) | 1 (1.4) | 2 (2.7) | 0 |
Nasopharyngitis | 0 | 0 | 2 (2.7) | 2 (2.6) |
Pharyngitis | 1 (1.3) | 1 (1.4) | 0 | 1 (1.3) |
Rhinitis | 0 | 2 (2.7) | 0 | 1 (1.3) |
Cough | 0 | 0 | 0 | 2 (2.6) |
Influenza | 1 (1.3) | 1 (1.4) | 0 | 0 |
Purulence | 0 | 0 | 1 (1.3) | 0 |
Respiratory tract infection | 0 | 0 | 0 | 1 (1.3) |
Urinary tract infection | 0 | 0 | 0 | 1 (1.3) |
Viral upper respiratory tract infection | 1 (1.3) | 0 | 0 | 0 |
Stomatitis | 0 | 0 | 0 | 1 (1.3) |
Chest pain | 1 (1.3) | 0 | 0 | 0 |
Contusiona | 0 | 0 | 0 | 1 (1.3) |
Skeletal injury | 0 | 0 | 0 | 1 (1.3) |